Diskusjon Triggere Porteføljer Aksjonærlister

ContextVision (CONTX)

Software/SaaS
#405

ContextVision stock-based incentive program - share transactions

Stockholm, March 29, 2021

The ContextVision AB:s Profit Sharing Foundation has sold and purchased shares in ContextVision AB in accordance with the rules related to the foundation.

The ContextVision AB:s Profit Sharing Foundation has sold 154,200 shares on March 19, at an average price of 20 NOK/share, in accordance with the rules related to the foundation. The sold shares were originally purchased in 2016, and according to the rules they must be sold after a period of 3 full calendar years, the year of purchase thereby not included. The net contribution after tax deductions, will be paid out to the employees.

The company achieved important goals during 2020 related to sales and new customers within the core business of image enhancement. As a result, SEK 202,000 were allocated to the foundation, and after tax deduction SEK 162,562 were transferred to the foundation. The foundation thereafter purchased 7,900 shares on March 29, at the average price of 20,05 NOK/share.

The ContextVision AB:s Profit Sharing Foundation’s total ownership after the transactions is now 159,800 shares.

Background:

In 2011, the board and management of ContextVision decided to introduce an incentive program through the creation of a profit-sharing foundation for its employees.

The program is intended to streamline the focus and efforts of all employees by allocating a part of the company’s net profits to a foundation that, in turn, will use the allocated funds to purchase ContextVision’s common stock on the Oslo Stock Exchange.

Senior management and the board of directors will each year formulate a number of operational and strategic targets to be achieved during the coming fiscal year.

According to the rules of the foundation, the shares bought each year will be kept for a period of 3 full calendar years. After that period, the shares will be sold and funds (less tax) will be paid to the employees.

For further information, please contact CFO Ann-Charlotte Linderoth,

e-mail: ann-charlotte.linderoth@contextvision.se

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

https://ml-eu.globenewswire.com/Resource/Download/c367170a-3078-4b45-b523-c54a81758c60

https://www.globenewswire.com/NewsRoom/ReleaseNg/400902672

#406

Tenker det kan ikke være så dårlig stelt når man driver med “profit sharing”. :grin:

#407
#408

Sakset fra HO:

Norne kom med en oppdatert analyse på fredag før Q1 rapporteringen den 22/4. Kun marginale endringer og uforandret kursmål på NOK 25.

Expecting more action post pandemic
We stay positive on ContextVision share ahead of 1Q report next week. The company is a clear market leader in the existing Medical Imaging business that allowed them to venture into very exciting Digital Pathology field, where they are at the forefront with the first commercial product INIFY Prostate. Thus, as the pandemic ebbs INIFY Prostate commercialization efforts will start yielding tangible results, which should also be reflected in the share price.

Investment case unchanged – Buy @ NOK 25/sh target price
Our Buy recommendation and NOK 25/sh target price is reiterated ahead of 1Q report. We are impressed by how the company’s existing Medical Imaging business managed to pay for an extensive development of Digital Pathology products. The company is a clear market and technology leader in Medical Imaging software, which we also believe makes them a prime candidate to succeed within Digital Pathology field. The quarters and years ahead are going to be exciting and we stay positive on the share.

#410

Markedsreaksjonen er ikke til å ta feil av, men personlig vil jeg si at covid-påvirkningen er ca som forventet og noe selskapet har varslet i både årsrapport og tidligere kvartalsrapporter. Jeg tror at dagens kurs vil vise seg som en gunstig inngangspris hvis en tenker 2-3 år frem.

#411

Dette var svakt, men de har selv varslet det.

Sitter ikke med aksjer i selskapet selv, men så nå at Norne har kommet med en oppdatering etter at tallene har kommet.
De opprettholder kursmålet på 25.

ContextVision reported weaker figures this morning affected by pandemic, but also due to increased commercialization efforts for Digital Pathology, which we view as positive. Solid sales are expected for 2021 form Medical Imaging due to pent up demand. Therefore, we stay positive on the stock.

1 Like
#412

Dette blir bra.

Gikk ut av DNO før de gikk 10 gangen. Ut av NEL på 4.50. Ut av Photocure på 69. Jeg vet å plukke de rette, men å sitte har jeg slitt med.

Denne gangen skal jeg av dyrkjøpt erfaring holde ut…

2 Likes
#413

Det stemmer vel ikke?

#414

2Q presentasjon nærmer seg. Hva kan vi vente? Etter det de har meddelt har de 2 store “referanse sentre”. Spørsmålet er, når er evalueringen ferdig? Måneder eller år? Når blir det kontrakter?

Siste informasjon fra selskapet var ved 1Q presentasjonen som jeg gjengir her:

Progress in establishing reference centers within digital pathology

STOCKHOLM – April 22, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today reports its first quarter results for 2021.

The quarter saw strong and promising progress within digital pathology and the company’s first product, INIFY Prostate Screening. While the ongoing pandemic slowed sales slightly, solid financials – paired with close dialogues with present and prospective clients – provide a positive outlook.

“Dr. Filippo Fraggetta – one of the leading pathologists in Europe and instrumental in the development of the product – confirms the preliminary results from the ongoing clinical study, indicating that using INIFY Prostate decreases variance between pathologists will benefit referrals and patients in the longer term. This is really great news”, says CEO Fredrik Palm at ContextVision.

European reference centers within digital pathology
The first quarter saw the additions of important reference centers. Installations were carried out at Vall d’Hebron University Hospital in Barcelona, as well as Hôpital de Bicêtre in Paris, a fully digitalized, high-throughput laboratory in the forefront of digital pathology in France.

“Installations and evaluations at key reference centers within digital pathology in Europe are of highest importance, adding laboratories like the ones in Paris and Barcelona is certainly in line with our strategy. INIFY Prostate’s state of the art technology, that it is both easy to install and user-friendly, are all important factors when digitalizing laboratories and easing the pathologists’ heavy workload”, says Palm.

In parallel, ContextVision proceeded in the first quarter with development of the next-generation product for prostate, as well as research within colorectal cancer.

Lower sales, but no lack of interest or demand
Sales continue to be affected by the pandemic situation, but the first quarter’s lower level in comparison with the previous quarter is also in part related to quarterly variations.

“What is most important is that there is no lack of interest or demand, nor are there any customer losses within medical imaging, so it is just a matter of persistence until we can return to the sales growth we normally would expect,” says Palm.

The financials are solid, with a cash position of close to SEK 50 million at the end of the quarter, allowing the company to continue its strategic process as planned.

#415

Ser ut som de er veldig aktive med markedsføring av INIFY, og at de nettopp har fått løsningen integrert i Sectra sin applikasjon sees på som et stort pluss med tanke på lett integrering.

Forventer også at salget av ultralyd har begynt økningen igjen I takt med gjenåpningen av sykehus etter pandemien. Det største spørsmålet jeg har er hvordan de jobber med INIFY og godkjenning/markedsføring i USA og Asia der de allerede har en god kundemasse. De må vel ha jobbet i kulissene for å komme igjennom FDA, noe som jeg tror vi plutselig kan få informasjon om.
Blir iallefall spennende å se hva Q2 bringer med både resultater og ny guiding :slight_smile:

1 Like
#416

STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.

Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.

INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.

“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,” says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.

“At Tufts Medical Center, we are in the process of digitalizing pathology,” says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. ”Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”

“ We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit cancer.osu.edu.

Tufts Medical Center is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children’s Hospital. Tufts MC’s renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.

###

About ContextVision

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools, and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

For further information, please contact ContextVision’s CEO, Fredrik Palm, at +46 76 870 25 43 or visit www.contextvision.com

Attachment

1 Like
#417

Dette er positivt. Kontraktene vil nok komme etterhvert.

#418

Avsluttet børsdagen på 20 i dag.

På tide å nå fjorårets topp for ett år siden på 24,50. Siden har kursen dalt med bunn på 16,21 16 mai. Foreløpig er det bare DP Prostata (AI). Tiden må snart være inne for EU sertifisering på tarm og så lunge. Det vil få opp interessen for selskapet…

#419

ContextVision: Best ever sales within Medical Imaging and rewarding feedback from INIFY Prostate evaluations

STOCKHOLM – August 12, 2021 - ContextVision, a medical technology software company specializing in image processing, delivered the Company’s best ever second quarter within Medical Imaging. Initial response from the ongoing clinical trials with the Company’s first digital pathology product, INIFY Prostate, are very promising.

Sales in the second quarter reached 24.4 MSEK (20,1), an 20% increase compared with the previous quarter, and an increase of 32% versus last year’s corresponding quarter when adjusted for currency exchange effects.

Impressive accuracy – is the feedback from evaluations sites within digital pathology
“ INIFY Prostate delivered impressive accuracy in it’s ongoing clinical evaluations. In the second quarter we expanded into the US getting two prestigious medical sites onboard for clinical testing ”, says CEO Fredrik Palm in ContextVision.

The company has intensified the interaction with new potential customers as well as deepened the relations with established sites and laboratories.

“ It is rewarding to see the positive response we get when we demonstrate how INIFY identifies and outlines cancer areas with an impressive accuracy. We continue to advance our position step by step within digital pathology ”, says Palm.

Significant pick up
ContextVision saw a significant pick up in revenue from its image enhancements software resulting in best second quarter ever, partly due to a catch up in the market, but also in a few cases due to timing of customer orders. Most of the increase is seen in ultrasound, mainly in the Asia region.

“ Medical Imaging is returning to normal. During the period we have signed new contracts with several key customers, continuing to strengthen and extend our long-term partnerships over multiple markets and product cycles. Our relentless dedication to make progress together with customers under present circumstances is a clear success factor, and I am optimistic that we now have seen the start of a stepwise return to our initial growth plan before Covid ”, says Palm.

New chairman elected in the quarter
In the second quarter Olof Sandén was elected as the Company’s new chairman of the board. Sandén brings extensive experience from international business and Medical device industry having had senior positions at Elekta, RISE, Business Sweden, BCG and others. Today he holds several board positions along with his daily work as a partner within an executive search firm.

“ Imaging has been and will continue to be a corners stone in developing better healthcare. ContextVision is extremely well positioned to play an important role in this development, from its image enhancement software to ContextVision’s new inroads into image analysis and AI supported decision making, we are uniquely positioned. I am excited to support ContextVision in delivering valuable solutions to the global healthcare market enabling further development of patient care ”, says Sandén

1 Like
#420

“Første resultater av de kliniske studiene på INIFY skal publiseres i slutten av august.”
Tror vi har et spennende halvår foran oss :slightly_smiling_face:

1 Like
#421

Veldig betryggende å se at veksten fortsetter og at nyvinninger innen AI ser ut til å ville slå til. De har CE-MERKET Inify Prostata og det vil skape bølger når tarm og lunge følger etter… Få på tekinvestor skjønner potensialet i denne aksjen. :wink:

2 Likes
#422

spennende! :relaxed:

#423

Sakset fra HO:

"Oppdatert analyse fra Norne etter Q2 rapporten. Det som er mest interessant i denne sammenlignet med forrige rapport fra Norne er siste setning:
Existing Medical Imaging business seems to be gaining speed as the pandemic-related restrictions are ending, while we are eagerly awaiting first results from the ongoing clinical evaluations within Digital Pathology as soon as this month.
Mao. mener Norne at CONTX allerede i løpet av august får svar på den kliniske evalueringen og at kontrakt kan inngås.

Very strong Medical Imaging performance while awaiting first encouraging data on INIFY Prostate

ContextVision’s 2Q report was marked by better-than-expected sales and increasing activity for the Digital Pathology field. Therefore, anticipating Medical Imaging to continue doing well and expecting first clinical evaluation results before month-end, we stay positive on the share at an unchanged TP of NOK 25/sh.

Impressive sales in 2Q despite strong negative FX impact
ContextVision’s 2Q sales came in at SEK 24m, 10% better than SEK 22m estimated by us. This is even more impressive having in mind the 9% negative FX impact on sales in the quarter due to strengthening of the SEK vs all main currencies. EBITDA was reported at around zero (SEK -0.1m) vs marginally positive figure (SEK 1.1m) in our model. The cash position was further strengthened and now stands above SEK 50m.

Medical Imaging segment rebounding after weak start of the year
Medical Imaging continued to develop well with strong sales and a 54% EBITDA margin. There were some catch up effects that drove 2Q sales, but activity is picking up in general and ContexVision is hopeful for these stronger sales to continue going forward.

Moving forward with Digital Pathology and feedback is great
As expected, no breaking news on Digital Pathology was announced. Gradual progress is made within the commercialization of the first product INIFY Prostate. New sites were signed for clinical evaluation (two sites in the US as mentioned before), while discussions with more clients are ongoing. Notably, preliminary feedback on INIFY Prostate from several test centres indicates impressive accuracy. More importantly, the first results of these evaluations are due this month, which we believe should act as a trigger for the stock.

Buy reiterated at the same TP of NOK 25/sh
Following the 2Q report, we reiterate our Buy recommendation at an unchanged TP of NOK 25/sh. We have made only small estimate adjustments on the revenue side, while costs were raised on the back of higher anticipated activity, as the pandemic ebbs. Existing Medical Imaging business seems to be gaining speed as the pandemic-related restrictions are ending, while we are eagerly awaiting first results from the ongoing clinical evaluations within Digital Pathology as soon as this month.

5 Likes
#424

“More importantly, the first results of these evaluations are due this month, which we believe should act as a trigger for the stock.”

Får inntrykk av at “noen” vet mer enn oss små aksjonærer.

#425

ContextVision: Assessing a Digital Pathology spin-off with a listing on Euronext Growth

STOCKHOLM – August 26, 2021 - ContextVision, a medical technology software company specializing in image processing and decision support tools within digital pathology, today announces that the Board of Directors of ContextVision is conducting a review of the company’s structure, and has initiated work assessing a spin-off of the Digital Pathology unit with a goal of listing the new entity on the Euronext Growth on the Oslo Stock Exchange. The review is expected to be concluded by the end of the fourth quarter 2021.

ContextVision’s Board of Directors believes a split of the Company – with one entity consisting of Medical Imaging, the other of Digital Pathology – could accelerate the long-term business growth and success of both entities, hence creating substantial shareholder value.

“Strong differentiated investor appeal”
Since the company’s inception nearly 40 years ago, ContextVision has become a global market leader within image enhancement, as a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world. Since 2015, the company is one of the pioneers within digital pathology, developing decision support tools for detecting prostate cancer using artificial intelligence and deep learning.

“ We believe the time is right to assess creating two separate companies. So far, we have benefited greatly from being one closely knit organization but going forward, we believe the company might prosper more as two separate entities. We have reached a stage where it is our responsibility to evaluate whether a full strategic focus on each business is more important than the synergies offered by continuing as one company ,” says CEO Fredrik Palm of ContextVision.

“ The Board of Directors and Management have for a while seen a split as a natural evolution of the company in order to maximize potential and long-term shareholder value. By splitting ContextVision, two clean-cut investment alternatives are formed, both with exciting futures and strong differentiated investor appeal ,” says chairman Olof Sandén of ContextVision.

Increased demand for core products
The Company’s core business, Medical Imaging, has never been as strong as now, delivering annual margins of around 40 percent over the last couple of years.

“ We see an increasing demand for our image quality products and believe that a full focus – with no disturbance from developing new technologies – will help further develop the Medical Imaging business, where ContextVision holds a unique market leader position ,” says Palm.

Last year, ContextVision saw the release of the company’s first digital pathology product, INIFY Prostate Screening. As it transitions into the next phase, the need to focus within the whole organization is clear.

“ INIFY Prostate is our market entrance product. It will be further developed for prostate as well as for additional cancer types, such as colorectal cancer. In addition, we are also considering other business opportunities that the digitalization of pathology offers. The market is maturing step by step, and has a huge potential ,” says Palm.

INIFY Prostate allows pathologists to focus their time on specimens with suspicious cancer and minimize time spent on benign tissue. It will facilitate the transformation of clinical pathology into a digital discipline, ultimately offering improved workflow and much higher quality and standardization. The predicting engine in the product is built on deep learning algorithms and offers top accuracy on a pixel level. It is trained on data generated with its patented MasterAnnotation™ method and verified by top pathologists.

“ The assessment of a split, initiated after the decision by the board, will be carried out during the fall and we estimate to communicate a final decision including details thereof before the end of the year ,” says Palm.

Fredrik Palm will lead the group assessing the split.

The company will hold a Q&A web conference on Sep 1st at 10:30-11:00 CEST – use the link below for registration.
https://attendee.gotowebinar.com/register/1160618503231913741

###

For further information, please contact ContextVision’s CEO, Fredrik Palm, fredrik.palm@contextvision.se or visit www.contextvision.com

3 Likes